Andrea Maderal
Dermatology · Miami, FLNPI 1326380924
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $21,450 of the $24,545 with a category attached, or 87.4%. Argenx US, Inc. accounts for 61.9% of it on its own, with 3 other manufacturers making up the rest.
Across 34 payments — averaging $721.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Argenx US, Inc.$15K
- Johnson & Johnson$9K
- Pfizer$381
- Novartis$197
Across 3 payments — averaging $17,041 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$33K
- E.r. Squibb & Sons, L.L.C.$18K
What the payments were for
- Consulting fees$21,45087%
- Travel & lodging$2,0278%
- Food & beverage$1,0674%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Argenx US, Inc. | 17 | $15,190 |
| Johnson & Johnson | 10 | $8,777 |
| Pfizer | 3 | $381 |
| Novartis | 4 | $197 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,545 in reported general payments places this provider in the 85th percentile of 1,147 dermatology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ThalomidThalidomide | 25 | $150,673 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 17 | $145,333 |
| OtezlaApremilast | 15 | $72,077 |
| XolairOmalizumab | 27 | $58,910 |
| Dupixent PenDupilumab | 14 | $51,011 |
| Mycophenolate Mofetil | 37 | $12,053 |
| Sildenafil Citrate | 16 | $5,255 |
| Tacrolimus | 45 | $4,295 |
| Ketoconazole | 206 | $3,322 |
| Fluorouracil | 31 | $2,073 |
| Cyclosporine ModifiedCyclosporine, Modified | 14 | $1,677 |
| Ammonium Lactate | 85 | $1,503 |
| Azelaic Acid | 12 | $1,382 |
| Fluocinolone Acetonide | 22 | $1,264 |
| Clobetasol Propionate | 38 | $1,233 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Miami
- Francisco KerdelMiami$2.1M
- Robert KirsnerMiami$1.4M
- Gil YosipovitchMiami$1M
- Mercedes GonzalezMiami$943K
- Heather Woolery LloydMiami$609K
- Hadar Lev-TovMiami$326K
- Lawrence SchachnerMiami$309K
- Giovanna CioccaMiami$222K
- Janice Lima MaribonaMiami$217K
- Jill WaibelMiami$116K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.